Results 201 to 210 of about 176,622 (333)

Long‐term outcomes of nationwide coordinated neovascular AMD treatment: A study based on Polish national registry

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate long‐term outcomes of anti‐VEGF therapy for nAMD using the Polish Retinal Therapeutic Program Monitoring Registry. Methods The cohort consisted of 63 840 eyes with nAMD qualified for treatment from 2016 to 2022, with follow‐up through 31 October 2023. Long‐term follow‐up (>5 years) was conducted for 7631 eyes.
Sławomir Teper, Daniel Ledwoń, Adam Sendecki, Patrycja Romaniszyn‐Kania, Aleksandra Tuszy, Julia Nycz, Andrzej W. Mitas, Małgorzata Figurska, Edward Wylęgała, Marek Rękas   +9 more
wiley   +1 more source

Association between induced organ atrophy assessed by artificial intelligence-generated automatic segmentation and efficacy of bevacizumab in combination with chemotherapy in metastatic colorectal cancer. [PDF]

Cancer Imaging
Laich M, Brugel M, Conze PH, Abbas M, Abdelghanie MB, Khemissa F, Kircher S, Le Malicot K, Lepage C, Aparicio T, Hoeffel C, Bouché O, Carlier C.   +12 more
europepmc   +1 more source

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, EarlyView.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Comparative Analysis of Maintenance Treatments in Patients with Newly Diagnosed Advanced Ovarian Cancer After First-Line Platinum-Based Regimens. [PDF]

Cancers (Basel)
Gasperoni L, Cancanelli L, Ossato A, Del Bono L, Vecchia S, Fontanella C, Damuzzo V, Messori A.   +7 more
europepmc   +1 more source

ZNF282 Promotes Colorectal Cancer Progression Possibly via E2F1 Activation

Cancer Science, EarlyView.
ZNF282 is a zinc finger protein overexpressed in colorectal cancer that facilitates tumor progression by promoting cell cycle progression via E2F1 activation. Our study demonstrates that ZNF282 expression is associated with poor prognosis and may serve as a novel prognostic biomarker and therapeutic target. ABSTRACT Colorectal cancer (CRC) is a leading
Tadashi Abe, Takaaki Masuda, Taro Tobo, Masahiro Hashimoto, Yusuke Nakano, Hideyuki Saito, Takashi Ofuchi, Tomohiko Ikehara, Akinori Tsujimoto, Takafumi Nakano, Katsushi Dairaku, Junichi Takahashi, Kensuke Koike, Koto Kawata, Yuki Ando, Kiyotaka Hosoda, Takanari Tatsumi, Kosuke Hirose, Satoshi Higuchi, Hajime Otsu, Yusuke Yonemura, Ken Eto, Toru Ikegami, Koshi Mimori   +23 more
wiley   +1 more source

The discovery of Bevacizumab. An historical reappraisal. [PDF]

Clin Exp Med
Ribatti D.
europepmc   +1 more source

Atezolizumab + Chemotherapy for Advanced Non‐Small Cell Lung Cancer in Japanese Clinical Practice (J‐TAIL‐2)

Cancer Science, EarlyView.
The J‐TAIL‐2 prospective, observational study evaluated atezolizumab combined with several chemotherapy regimens in patients with advanced/metastatic non‐small cell lung cancer in routine clinical practice in Japan. The real‐world efficacy and safety of each atezolizumab combination were found to be comparable to those seen in the relevant global ...
Hiroshige Yoshioka, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Ichiro Yoshino, Toshihiro Misumi, Yasutaka Watanabe, Akito Hata, Akira Kisohara, Shoichi Kuyama, Masafumi Yamaguchi, Asako Miwa, Shunichiro Iwasawa, Misa Tanaka, Akihiko Gemma   +19 more
wiley   +1 more source

The effect of combination therapy on Bevacizumab, Carmustine, and Metformin chemotherapy drugs on the fluctuating performance expression of TLR2, TLR6, and IL-6 genes in the cell line of brain glioblastoma. [PDF]

Cancer Cell Int
Norollahi SE, Yousefi B, Yousefzadeh-Chabok S, Nejatifar F, Samadian M, Evazalipour M, Eftekhary M, Akhlaghi MF, Mirzajani E, Rashidy-Pour A, Samadani AA.   +10 more
europepmc   +1 more source

BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study

, 2018
Peter A. Fasching, Sibylle Loibl, Chunling Hu, Steven N. Hart, Hermela Shimelis, Raymond M. Moore, Christian Schem, Hans Tesch, Michael Untch, J. Hilfrich, Mahdi Rezai, Bernd Gerber, Serban Dan Costa, Jens‐Uwe Blohmer, Tanja Fehm, Jens Huober, Cornelia Liedtke, Richard M. Weinshilboum, Liewei Wang, James N. Ingle, Volkmar Müller, Valentina Nekljudova, Karsten E. Weber, Brigitte Rack, Matthias Rübner, Gϋnter von Minckwitz, Fergus J. Couch   +26 more
openalex   +2 more sources

Outcomes After Switching to Faricimab in Neovascular Age‐Related Macular Degeneration: Data From the Fight Retinal Blindness! Registry

Clinical &Experimental Ophthalmology, EarlyView.
ABSTRACT Background We aimed to describe 1‐year outcomes of eyes switched to faricimab from first‐generation vascular endothelial growth factor (VEGF) inhibitors for neovascular age‐related macular degeneration (nAMD) in routine care. Methods Multicentre, observational study of 383 eyes tracked in the Fight Retinal Blindness!
Adrian Hunt, Yohei Hashimoto, Stephanie Young, Jennifer Arnold, Justin Game, Claire Hooper, Andrew Field, Richard Barry, Daniel Barthelmes, Mark Gillies   +9 more
wiley   +1 more source